Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Pediatric Blood & Cancer

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.23380PMID 22021170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peg-asparaginase for acute lymphoblastic leukemia

  2010cited by this paper
• Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia

  2010cited by this paper
• Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia

  2010cited by this paper
• Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.

  2010cited by this paper
• Pegasparaginase: where do we stand?

  2009cited by this paper
• Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.

  2009cited by this paper
• How to predict and prevent the immunogenicity of therapeutic proteins.

  2008cited by this paper
• Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

  2007cited by this paper
• Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.

  2007cited by this paper
• A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.

  2002cited by this paper
• Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

  2001cited by this paper
• Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

  1998cited by this paper
• Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia.

  1979cited by this paper
• Where Do We Stand?

  1891cited by this paper

• An anti-CD19-exosome delivery system navigates the blood–brain barrier for targeting of central nervous system lymphoma

  2025cites this paper
• Peg-asparaginase associated toxicities in children with acute lymphoblastic leukemia: A single-center cross-sectional study

  2024cites this paper
• Nanoparticles in Allergen‐Delivery Systems for Allergen‐Specific Immunotherapy

  2024cites this paper
• Exosome-based nanoparticles and cancer immunotherapy.

  2024cites this paper
• A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native E. coli asparaginase in children with acute lymphoblastic leukemia

  2023cites this paper
• Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control

  2023cites this paper
• Pegaspargase: Two Pediatric Case Studies of Delayed Urticaria Preceding Anaphylactic Reactions Postadministration.

  2021cites this paper
• Premedication prior to PEG‐asparaginase is cost‐effective in pediatric patients with acute lymphoblastic leukemia

  2021cites this paper
• Hypersensitivity Rates in Pediatric Patients Receiving Intravenous or Intramuscular Asparaginase Agents

  2020cites this paper
• mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach

  2020cites this paper
• Prospective, real‐time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non‐Hodgkin lymphoma in Belgium

  2020cites this paper
• AWARD NUMBER: W81XWH-17-1-0470 TITLE: Targeted Lung-Derived Proteins as a Therapeutic Strategy Against Breast Cancer Metastasis

  2019cites this paper
• B-Cell Precursor ALL

  2019cites this paper
• Extracellular Vesicles as Novel Nanocarriers for Therapeutic Delivery

  2019cites this paper
• Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives

  2019cites this paper
• Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity

  2018cites this paper
• Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG‐asparaginase in children with acute lymphoblastic leukemia: A meta‐analysis and systematic review

  2018cites this paper
• Reply to: Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEG‐asparaginase in children with acute lymphoblastic leukemia: A meta‐analysis and systematic review

  2018cites this paper
• Identification and management in patients with acute lymphoblastic leukemia

  2018cites this paper
• Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials

  2018influential citation
• Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

  2018cites this paper
• Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection – a review

  2017cites this paper
• Asparaginase use for the treatment of acute lymphoblastic leukemia.

  2017cites this paper
• Asparaginase Toxicities: Identification and management in patients with acute lymphoblastic leukemia

  2017cites this paper
• Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia

  2017cites this paper
• From the Children’s Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education

  2017cites this paper
• Comparison of hypersensitivity rates to intravenous and intramuscular PEG‐asparaginase in children with acute lymphoblastic leukemia: A meta‐analysis and systematic review

  2017cites this paper
• Asparaginase use for the treatment of acute lymphoblastic leukemia

  2017cites this paper
• Allergic reactions associated with pegaspargase in adults

  2016cites this paper
• Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells.

  2016cites this paper
• Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group

  2016cites this paper
• Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada

  2016cites this paper
• The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience

  2016cites this paper
• Development and regulation of exosome-based therapy products.

  2016cites this paper
• The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection

  2015cites this paper
• PEG‐asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol

  2015cites this paper
• Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review

  2015cites this paper
• A Phase 2 study of L‐asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL‐SA2‐2008 study

  2015cites this paper
• Anaphylactic reaction to polyethylene glycol‐conjugated asparaginase: Premedication and desensitization may not be sufficient

  2014cites this paper
• How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia.

  2014cites this paper
• Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate‐use trial

  2014cites this paper
• Comparison of Allergic Reactions to Intravenous and Intramuscular Pegaspargase in Children with Acute Lymphoblastic Leukemia

  2014cites this paper
• Treatment of Children with Advanced-Stage Lymphoblastic Lymphoma with Pegaspargase

  2014cites this paper
• Czynniki warunkujące aktywność terapeutyczną L-asparaginazy

  2014cites this paper
• Managing Hypersensitivity to Asparaginase in Pediatrics, Adolescents, and Young Adults

  2013cites this paper
• Questioning the use of PEGylation for drug delivery

  2013cites this paper
• [Update on L-asparaginase treatment in paediatrics].

  2013cites this paper
• Administration, distribution, metabolism and elimination of polymer therapeutics.

  2012cites this paper